ivozall
orphelia pharma sas - klofarabin - predkroglomerna limfoblastna levkemija limfoma - antineoplastična sredstva - zdravljenje akutno limfoblastno levkemijo, (vse), pri pediatričnih bolnikih, ki so ponovila ali so ognjevarni po prejemu vsaj dve predhodni režimi in če ni druge možnosti zdravljenja, predvidene za posledico trajno odgovor. varnost in učinkovitost sta bili ocenjeni pri študijah pri bolnikih ≤ 21 let pri začetni diagnozi.
retsevmo
eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastična sredstva - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.
dasatinib accord
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastična sredstva - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.
dasatinib accordpharma
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastična sredstva - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.
caduet 5 mg/10 mg filmsko obložene tablete
pfizer luxembourg sarl - amlodipin; atorvastatin - filmsko obložena tableta - amlodipin 5 mg / 1 tableta atorvastatin10 mg / 1 tableta; atorvastatin 10 mg / 1 tableta - atorvastatin in amlodipin
caduet 10 mg/10 mg filmsko obložene tablete
pfizer luxembourg sarl - amlodipin; atorvastatin - filmsko obložena tableta - amlodipin 10 mg / 1 tableta atorvastatin10 mg / 1 tableta; atorvastatin 10 mg / 1 tableta - atorvastatin in amlodipin
norvasc 5 mg tablete
pfizer luxembourg sarl - amlodipin - tableta - amlodipin 5 mg / 1 tableta - amlodipin
norvasc 10 mg tablete
pfizer luxembourg sarl - amlodipin - tableta - amlodipin 10 mg / 1 tableta - amlodipin
caduet 5 mg/10 mg filmsko obložene tablete
pfizer luxembourg sarl - amlodipin; atorvastatin - filmsko obložena tableta - amlodipin 5 mg / 1 tableta atorvastatin10 mg / 1 tableta; atorvastatin 10 mg / 1 tableta - atorvastatin in amlodipin
caduet 10 mg/10 mg filmsko obložene tablete
pfizer luxembourg sarl - amlodipin, atorvastatin - filmsko obložena tableta - amlodipin 10 mg / 1 tableta; atorvastatin 10 mg / 1 tableta - atorvastatin in amlodipin